Healthcare Sales & Marketing Network News: canagliflozin

Searching News Database: canagliflozin

HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 16 Mar 2018
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
Devices Monitoring Endocrinology Acquisitions

HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology

HSMN NewsFeed - 5 Oct 2017
Animas Corporation to Close Operations and Exit Insulin Pump Market
Devices Endocrinology

HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.